Health
Obesity Drug Study Points to Effectiveness in Curbing Addictions
- Research followed over 215,000 GLP-1 users for years
- Findings point to potential role in cocaine, opioid addiction
This article is for subscribers only.
One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their impact on the brain, pointing to benefits from addiction to schizophrenia.
The research tracked the effects of GLP-1 receptor agonists on diabetic US veterans for up to five years, making it one of the most extensive so far on a class of medicines that includes Novo Nordisk A/S’s Wegovy and Eli Lilly & Co.’s Zepbound.